Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Citius Pharmaceuticals (Nasdaq: CTXR) will participate in the Jefferies London Healthcare Conference in London, United Kingdom, on November 16–19, 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) will participate in the Jefferies London Healthcare Conference in London, United Kingdom, on November 16–19, 2026. Chairman and CEO Leonard Mazur will hold one-on-one business development meetings and discuss recent developments, including ongoing commercialization of LYMPHIR by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/11/2026 - 08:30 AM EST

Chairman and CEO Leonard Mazur to host one-on-one business development meetings

CRANFORD, N.J., Nov. 11, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Leonard Mazur, Chairman and Chief Executive Officer, will participate in the Jefferies London Healthcare Conference, taking place November 16–19, 2026, in London, United Kingdom.

Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR^® (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

Conference Details:

Conference: Jefferies London Healthcare Conference
Dates: November 16–19, 2026
Location: Waldorf Hilton & ME Hotels, London, United Kingdom
Format: one-on-one meetings

One-on-one meetings with management may be scheduled by contacting a conference representative or the Company's investor relations team.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com

Citius Pharmaceuticals, a late-stage biopharmaceutical company